COMMUNIQUÉS West-GlobeNewswire

ACARIZAX® approved in Canada for treatment of young children
07/03/2025
ALK ( ALKB:DC / OMX: ALK B ) today announced that Health Canada has approved ALK’s ACARIZAX ® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX ® is now indicated for treatment of [...]
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
07/03/2025
SEATTLE and VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
07/03/2025
THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare [...]
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
07/03/2025
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/03/2025
DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Raw Garden Introduces Sprout™ Vape, Pioneering Terpene-Safe Plastic for Cannabis Hardware
06/03/2025
California’s leading cannabis extract company finds a cleaner alternative to commonly used plastic for vape hardware after testing reveals potential health risks SANTA BARBARA, Calif., March 06, 2025 (GLOBE NEWSWIRE [...]
Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting
06/03/2025
AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of [...]
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
06/03/2025
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial Severe flu season enables potential mid-year assessment of efficacy Closed $105.0 million financing with new and existing investors Significantly expanded [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/03/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mars 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
06/03/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, March 06, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
06/03/2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
06/03/2025
- Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) [...]
CooperCompanies Announces First Quarter 2025 Results
06/03/2025
SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. [...]
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
06/03/2025
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for [...]
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
06/03/2025
- Continued progress with lead program, CX-2051 (EpCAM PROBODY ® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY ® [...]
TerrAscend Reports Fourth Quarter and Full Year 2024 Financial Results
06/03/2025
Fourth Quarter Net Revenue of $74.4 million, up 0.3% from $74.2 million in the third quarter of 2024 Fourth Quarter Gross Profit Margin of 50.2%, up 140 basis points from 48.8% in the third quarter of 2024 Full Year [...]
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
06/03/2025
– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award of Fast Track [...]
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06/03/2025
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple [...]
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
06/03/2025
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target [...]

Pages